Perdita Taylor-Zapata

Learn More
BACKGROUND Lithium is a benchmark treatment for bipolar illness in adults. However, there has been relatively little methodologically stringent research regarding the use of lithium in youth suffering from bipolarity. METHODS Under the auspices of the Best Pharmaceuticals for Children Act (BPCA), a Written Request (WR) pertaining to the study of lithium(More)
OBJECTIVE The primary goal of this exploratory study was to obtain data that could lead to evidence-based dosing strategies for lithium in children and adolescents suffering from bipolar I disorder. METHODS Outpatients aged 7-17 years meeting Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic criteria for bipolar I disorder(More)
  • Amy Susan Barone, Denise Blaney, Meredith Casey, Martha Chuk, Mark Donoghue, Kieran +10 others
  • 2014
Purpose The purpose of this call was to discuss the following:  Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) meeting scheduled for December 11–12, 2014  Tentative list of products: – Ganetespib (STA 9090) – NKTR-102 (etirinotecan pegol) – R06839921  Other products of potential interest: Lymphoseek (technetium Tc 99m(More)
OBJECTIVE This study examined the long-term effectiveness of lithium for the treatment of pediatric bipolar disorder within the context of combination mood stabilizer therapy for refractory mania and pharmacological treatment of comorbid psychiatric conditions. METHODS Outpatients, ages 7-17 years, meeting American Psychiatric Association, diagnostic and(More)
This study examines the pharmacokinetics of oral doses of lithium carbonate immediate-release capsules after administration of 600 or 900 mg in children and adolescents with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, bipolar I disorder. Lithium plasma concentrations were followed over 48 to 72 hours in 39 subjects (20 male and 19(More)
  • 1